Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Decline in Short Interest

Posted by Brian Himes on Jul 13th, 2026

Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) saw a large drop in short interest in June. As of June 30th, there was short interest totaling 112,788 shares, a drop of 94.4% from the June 15th total of 2,012,417 shares. Based on an average daily trading volume, of 23,583 shares, the days-to-cover ratio is currently 4.8 days. Approximately 12.4% of the company’s shares are sold short.

Quince Therapeutics Stock Performance

Quince Therapeutics stock traded up $0.05 during midday trading on Friday, hitting $17.54. 23,629 shares of the company’s stock were exchanged, compared to its average volume of 25,060. Quince Therapeutics has a 12 month low of $15.10 and a 12 month high of $909.98. The firm has a 50-day moving average of $20.66 and a two-hundred day moving average of $141.94. The company has a market cap of $17.19 million, a PE ratio of -0.08 and a beta of 1.40.

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($26.00) by $25.41. As a group, equities analysts expect that Quince Therapeutics will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Quince Therapeutics

Large investors have recently bought and sold shares of the business. Nantahala Capital Management LLC lifted its holdings in Quince Therapeutics by 21.6% during the third quarter. Nantahala Capital Management LLC now owns 3,073,729 shares of the company’s stock worth $5,010,000 after buying an additional 545,427 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Quince Therapeutics in the 4th quarter valued at $7,538,000. Vanguard Group Inc. raised its position in shares of Quince Therapeutics by 21.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock worth $2,874,000 after acquiring an additional 309,349 shares in the last quarter. Millennium Management LLC raised its position in shares of Quince Therapeutics by 1,152.9% in the 3rd quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock worth $2,260,000 after acquiring an additional 1,276,094 shares in the last quarter. Finally, Almitas Capital LLC raised its position in shares of Quince Therapeutics by 88.0% in the 4th quarter. Almitas Capital LLC now owns 930,134 shares of the company’s stock worth $3,116,000 after acquiring an additional 435,356 shares in the last quarter. Institutional investors own 30.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on QNCX shares. Wall Street Zen upgraded shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Weiss Ratings downgraded shares of Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Lifesci Capital upgraded Quince Therapeutics to a “strong-buy” rating in a report on Monday, June 29th. Zacks Research raised Quince Therapeutics to a “hold” rating in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald assumed coverage on Quince Therapeutics in a report on Tuesday, June 23rd. They set an “overweight” rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $690.00.

Get Our Latest Research Report on Quince Therapeutics

Quince Therapeutics Company Profile

(Get Free Report)

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.